Education
About Us
Working with TipRanks
Follow Us
Predictive Oncology Inc (POAI)
NASDAQ:POAI
Top Page
Predictive Oncology
(NASDAQ:POAI)
Rating:38Underperform
Price Target:
$0.50
▼(-35.90%Downside)
Positive Factors
Technology
The proprietary AI platform PEDAL has demonstrated the potential to identify biomarkers in cancer patients, making it an attractive licensing target.
Negative Factors
Financial Performance
Predictive Oncology reported lower than expected revenue for 3Q24, indicating potential financial challenges.
Strategic Uncertainty
The company is undergoing a strategic review, which includes evaluating alternatives like a sale of the company or its assets, creating uncertainty.
Predictive Oncology (POAI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.60M
Dividend YieldN/A
Average Volume (3M)140.16K
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue Growth-31.31%
EPS Growth49.27%
CountryUS
Employees23
SectorHealthcare
Sector Strength40
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.34
Shares Outstanding9,613,339
10 Day Avg. Volume208,920
30 Day Avg. Volume140,162
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-39.24
Price to Sales (P/S)0.00
P/FCF Ratio-0.84
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit11.87
Enterprise Value/Ebitda-0.13
Forecast
1Y Price Target
$1.00Price Target Upside28.21% Upside
Rating ConsensusHold
Number of Analyst Covering0
Predictive Oncology Business Overview & Revenue Model
Company DescriptionPredictive Oncology (POAI) is a biotechnology company focused on the development of innovative solutions in the field of cancer research and treatment. The company leverages artificial intelligence (AI) and machine learning to enhance the precision and effectiveness of oncology therapies. POAI operates across multiple sectors, including drug discovery, personalized medicine, and biopharmaceutical research, providing advanced tools and technologies to improve patient outcomes.
How the Company Makes MoneyPredictive Oncology makes money through a diversified revenue model that includes collaborations and partnerships with pharmaceutical and biotechnology companies, as well as research institutions. The company generates income by offering its proprietary AI-driven platforms and databases, which facilitate drug discovery and development. Licensing agreements for its technology and data, as well as service contracts for conducting research and development projects, are also key revenue streams. Additionally, POAI may earn revenue from grants, strategic alliances, and potential commercialization of its own therapeutic products in the future.
Predictive Oncology Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q2-2024)
| % Change Since: -27.10%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant advancements in AI-driven biomarker discovery, strategic partnerships, and cost reduction initiatives, despite a decline in quarterly revenue and consolidation of non-profitable operations.Q2-2024 Updates
Positive Updates
Successful Retrospective Ovarian Cancer Study
Completion of a multiyear ovarian cancer study with UPMC Magee-Womens Hospital, expanding AI capabilities to discover novel biomarkers for oncology.
Launch of 3D Cell Culture Technology
Introduction of a novel 3D cell culture technology that mimics human tissue architecture more closely, enhancing drug candidate testing and reducing development costs.
ACE Initiative and Collaboration
First collaboration with the University of Michigan under the ACE program, providing access to a large library of natural product drug candidates.
Cost Reduction Initiative
Strategic cost reduction measures, including consolidation of operations from Birmingham to Pittsburgh, expected to reduce annual cash usage by $2.5 million.
Capital Raises
Raised $5.0 million through capital raises to bolster cash balance and extend runway.
Negative Updates
Revenue Decline
Decrease in revenue to $279,000 for Q2 2024 from $490,000 in Q2 2023, primarily from the Egan operating segment.
Birmingham Operations Consolidation
Consolidation of Birmingham operations due to lack of profitability, with the segment generating a net loss of $2.0 million in 2023.
Cash and Equity Reduction
Reduction in cash and cash equivalents to $5.3 million and stockholders' equity to $4.1 million as of June 30, 2024, compared to $8.7 million and $8.3 million respectively as of December 31, 2023.
Company Guidance
During the Predictive Oncology Second Quarter 2024 Earnings Call, the company provided guidance on several strategic initiatives and financial metrics. Key highlights included the completion of a multiyear ovarian cancer study, which utilized data from 235 patients and resulted in the training of 160 predictive models with high accuracy. The company also launched a novel 3D cell culture technology and reported progress in its ACE initiative, forming a collaboration with the University of Michigan. Financially, Predictive Oncology reported a net loss of $3.2 million for the quarter, with a revenue of $279,000, compared to $490,000 in the previous year. They highlighted a strategic cost reduction initiative expected to save approximately $2.5 million annually, and capital raises totaling $5.0 million to bolster their cash position.Predictive Oncology Financial Statement Overview
Summary
Predictive Oncology faces significant financial challenges with declining revenues, negative profit margins, and deteriorating liquidity and solvency metrics. The company must address operational inefficiencies and stabilize its financial position.Income Statement
The company shows a declining revenue trend with a negative revenue growth rate over the years. Gross profit margin has decreased from 64.7% in 2023 to 49.1% in 2024. The net profit margin is severely low due to net losses. EBIT and EBITDA margins are negative, indicating operational inefficiencies.35
Negative
Balance Sheet
The balance sheet reveals financial instability with a negative stockholders' equity in 2024, indicating potential solvency issues. Debt-to-equity ratio is not applicable due to negative equity. The equity ratio is negative, reflecting a concerning capital structure.25
Negative
Cash Flow
Operating cash flows remain negative, highlighting ongoing liquidity challenges. Free cash flow is also negative, but there is a slight improvement in free cash flow growth rate from 2023 to 2024. The operating cash flow to net income ratio is negative, indicating inefficiencies in converting income to cash.40
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.62M | 1.78M | 1.51M | 1.42M | 1.25M |
| Gross Profit | 797.68K | 1.15M | 1.00M | 933.66K | 805.08K |
| EBITDA | -10.16M | -13.18M | -13.95M | -12.13M | -11.46M |
| Net Income | -12.20M | -13.98M | -36.21M | -19.66M | -37.70M |
Balance Sheet | |||||
| Total Assets | 4.97M | 14.42M | 25.73M | 43.77M | 13.06M |
| Cash, Cash Equivalents and Short-Term Investments | 734.67K | 8.73M | 22.07M | 28.20M | 678.33K |
| Total Debt | 2.13M | 2.86M | 180.32K | 879.33K | 5.87M |
| Total Liabilities | 5.18M | 6.15M | 3.97M | 3.51M | 10.42M |
| Stockholders Equity | -202.61K | 8.27M | 21.77M | 40.27M | 2.64M |
Cash Flow | |||||
| Free Cash Flow | -10.98M | -13.49M | -12.85M | -13.17M | -12.62M |
| Operating Cash Flow | -10.97M | -13.19M | -12.37M | -12.21M | -12.26M |
| Investing Cash Flow | -9.51K | -302.37K | -475.70K | -10.61M | -167.46K |
| Financing Cash Flow | 3.94M | 148.90K | 6.72M | 50.34M | 12.95M |
Predictive Oncology Technical Analysis
Negative
0.78
Price Trends
0.94
Negative
1.06
Negative
1.01
Negative
Market Momentum
-0.04
Positive
31.64
Neutral
43.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For POAI, the sentiment is Negative. The current price of 0.78 is below the 20-day moving average (MA) of 0.84, below the 50-day MA of 0.94, and below the 200-day MA of 1.01, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 31.64 is Neutral, neither overbought nor oversold. The STOCH value of 43.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for POAI.
Predictive Oncology Risk Analysis
Predictive Oncology disclosed 41 risk factors in its most recent earnings report. Predictive Oncology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Predictive Oncology Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $26.11M | ― | -62.82% | ― | 115.94% | 17.42% | |
52 Neutral | $7.39B | >-0.01 | -63.86% | 2.36% | 16.15% | 0.36% | |
51 Neutral | $20.06M | ― | -25.89% | ― | -16.05% | -195.28% | |
49 Neutral | $19.04M | ― | -138.80% | ― | -14.41% | -549.88% | |
46 Neutral | $7.73M | ― | -80.71% | ― | -2.06% | 49.73% | |
38 Underperform | $7.60M | ― | -504.16% | ― | -31.31% | 49.27% |
* Healthcare Sector Average
Performance Comparison
POAI
Predictive Oncology
0.78
-0.39
-33.33%
HBIO
Harvard Bioscience
0.40
-2.78
-87.42%
RVP
Retractable Technologies
0.67
-0.46
-40.71%
EKSO
EKSO BIONICS
3.32
-16.18
-82.97%
NXGL
NexGel Inc
2.41
0.31
14.76%
Predictive Oncology Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Predictive Oncology Faces Nasdaq Non-Compliance Notice
Negative
Jul 11, 2025
On July 8, 2025, Predictive Oncology received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement, as its stock price had closed below $1.00 for 30 consecutive business days. The company has until January 5, 2026, to regain compliance by achieving a stock price of at least $1.00 for 10 consecutive days. Failure to comply may result in delisting, though the company may be eligible for additional time if it meets other listing standards. Predictive Oncology is actively monitoring its stock price and considering options to address the issue.
The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Private Placements and FinancingRegulatory Filings and Compliance
Predictive Oncology Finalizes Stock Exchange Purchase Agreement
Neutral
Jul 8, 2025
Predictive Oncology has entered into a Stock Exchange Purchase Agreement (SEPA) with an accredited investor, allowing the issuance and sale of shares of Common Stock. This transaction is conducted under the exemptions from registration requirements of the Securities Act, potentially impacting the company’s financial operations and investor relations.
The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Delistings and Listing ChangesRegulatory Filings and Compliance
Predictive Oncology Faces Nasdaq Delisting Notice
Negative
Jun 11, 2025
On June 9, 2025, Predictive Oncology Inc. received a notice from Nasdaq indicating its failure to meet the minimum stockholders’ equity requirement, leading to a potential delisting from the Nasdaq Capital Market. The company has requested a hearing to appeal this decision, which temporarily halts the delisting process, but there is no guarantee of a favorable outcome. Predictive Oncology is exploring options to regain compliance with Nasdaq’s listing requirements.
The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.